A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
This pilot clinical trial studies how rituximab and latent membrane protein (LMP)-specific T-cells work in treating pediatric solid organ recipients with Epstein-Barr virus-positive, cluster of differentiation (CD)20-positive post-transplant lymphoproliferative disorder.
The purpose of this study is to determine the feasibility of treating pediatric and young adult solid organ transplant recipients with newly diagnosed or recurrent Epstein-Barr virus (EBV)-positive CD20-positive post-transplant lymphoproliferative disease (PTLD) with a novel T cell therapeutic, allogeneic Latent Membrane Protein(LMP)1/LMP2-specific cytotoxic T-lymphocytes (third party latent membrane protein [LMP]-specific T cells), in a cooperative group setting.
- IRB Number: 1704975155 (PHO-FALLON-COG-ANHL1522)
- Research Study Identifier: TX7739
- Principal Investigator: Kamnesh Pradhan, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required